Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jul;25(4):401-3.

[High Intensity Focused Ultrasound Therapy Combined With Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma]

[Article in Chinese]
Affiliations
  • PMID: 12921577
Clinical Trial

[High Intensity Focused Ultrasound Therapy Combined With Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma]

[Article in Chinese]
Cheng-bing Jin et al. Zhonghua Zhong Liu Za Zhi. .

Abstract

Objective: To study high intensity focused ultrasound (HIFU) therapy combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC).

Methods: Fifty patients with unresectable HCC (TNM stage IV) were randomized into a TACE (T) group and a TACE plus HIFU (T + H) group. Twenty-six patients underwent TACE alone, and 24 HIFU ablation 2 - 3 weeks after TACE. The mean follow-up time for all patients was 8.16 +/- 2.79 months (range 3 to 24 months). The median survival, 6-month-, 1-year survival rates and average survival of patients who died were calculated by Kaplan-Meier method and Fisher exact test.

Results: The median survival time, 6-month and 1-year survival rates were 11.3 months, 80.4 - 85.4% and 42.9% in T + H group, in contrast to 4 months, 13.2% and 0% in T group with significant differences (P < 0.01). The average survival time of patients who died was 10.21 +/- 4.12 months in T + H group, as compared with 4.35 +/- 2.39 months in T group also with significant differences (P < 0.01).

Conclusion: High intensity focused ultrasound therapy (HIFU) combined with transcatheter arterial chemoembolization (TACE), being better than TACE alone, may become one of the most effective treatments for patients with unresectable HCC.

Similar articles

See all similar articles

Cited by 4 articles

Publication types

MeSH terms

Feedback